Recombinant adeno-associated virus mediated gene transfer in a mouse model for homocystinuria

Experimental and Molecular Medicine

Volumn 38, Issue 6, 2006, Pages 652-661

  Park, Eun Sook ^a   Oh, Hyun Jeong ^b   Kruger, Warren D ^c   Jung, Sung Chul ^d   Lee, Jin Sung ^a,e  

^a Yonsei University   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c FOX CHASE CANCER CENTER   (United States)

^d Ewha Womans University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

Cystathionine synthase; Dependovirus; Gene therapy; Homocysteine; Homocystinuria; Mouse

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; METHIONINE; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GROWTH RETARDATION; HOMOCYSTINURIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SURVIVAL; TISSUE DISTRIBUTION; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; DEPENDOVIRUS; MUS;

EID: 33846246772     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2006.77     Document Type: Article

References (36)

1. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52
2. Bateman A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem Sci 1997;22:12-3
3. Boers GH, Smals AG, Trijbels FJ. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15
4. Buning H, Nicklin SA, Perabo L, Hallek M, Baker AH. AAV-based gene transfer. Curr Opin Mol Ther 2003;5:367-75
5. Bueler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem 1999;380:613-22
6. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci 2000;97:3428-32
7. Denis CV, Terraube V, Robert K, Janel N. Elevated plasma von Willebrand factor in a murine model of severe hyperhomocysteinemia. Thromb Haemost 2003;90:362-4
8. Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000;26:219-25
9. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003;14:1079-88
10. Guba SC, Fink LM, Fonseca VA. Hyperhomocysteinemia-an emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996;106:709-22
11. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno- associated virus vectors with different serotypes. J Virol 2000;74:1524-32
12. Janosik M, Kery V, Gaustadnes M, Maclean KN, Kraus JP. Regulation of human cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for two catalytically active conformations involving an autoinhibitory domain in the C-terminal region. Biochemistry 2001;400:10625-33
13. Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci 2001;98:2676-81
14. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-61
15. Kery V, Poneleit L, Kraus JP. Trypsin cleavage of human cystathionine beta-synthase into an evolutionarily conserved active core: structural and functional consequences. Arch Biochem Biophys 1998;355:222-32
16. Kraus JP. Cystathionine beta-synthase (human). Methods Enzymol 1987;143:388-94
17. Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, Sperandeo MP, Sebastio G, de Franchis R, Andria G, Kluijtmans LA, Blom H, Boers GH, Gordon RB, Kamoun P, Tsai MY, Kruger WD, Koch HG, Ohura T, Gaustadnes M. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 1999;13:362-375
18. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-72
19. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, Fowler B, Grobe H, Schwetzer L. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1 31
20. Mudd SH, Levy HL, Skovby F. Disorders in transsulfuration. In The Metabolic and Molecular Bases of Inherited Disease (Scriver CR, Beaudet A, Sly W , Valle D, eds), 2001, 2007-56, McGraw-Hill, New York
21. Oh HJ, Park ES, Kang S, Jo I, Jung SC. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector mediated gene transfer. Pediatr Res 2004;56:278-84
22. Oliveriusova J, Kery V, Maclean KN, Kraus JP. Deletion mutagenesis of human cystathionine beta-synthase Impact on activity, oligomeric status, and S-adenosylmethionine regulation. J Biol Chem 2002;277:48386-94
23. Robert K, Chasse JF, Santiard-Baron D, Vayssettes C, Chabli A, Aupetit J, Maeda N, Kamoun P, London J, Janel N. Altered gene expression in liver from a murine model of hyperhomocysteinemia. J Biol Chem 2003a;278:31504-11
24. Robert K, Vialard F, Thiery E, Toyama K, Sinet PM, Janel N, London J. Expression of the cystathionine beta synthase (CBS) gene during mouse development and immunolocalization in adult brain. J Histochem Cytochem 2003b;51:363-71
25. Schwahn BC, Wendel U, Lussier-Cacan S, Mar MH, Zeisel SH, Leclerc D, Castro C, Garrow TA, Rozen R. Effects of betaine in a murine model of mild cystathionine-beta-synthase deficiency. Metabolism 2004;53:594-9
26. Shan X, Kruger WD. Correction of disease-causing CBS mutations in yeast. Nat Genet 1998;19:91-3
27. Shan X, Dunbrack RL, Christopher SA, Kruger WD. Mutations in the regulatory domain of cystathionine beta synthase can functionally suppress patient-derived mutations in cis. Hum Mol Genet 2001;15:635-43
28. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM , Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997;16:270-6
29. Snyder RO. Adeno-associated virus-mediated gene therapy. J Gene Med 1999;1:166-75
30. Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci 2002;99:13777-82
31. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, Maeda N. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci 1995;92:1585-9
32. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 2002;22:34-41
33. Wilcken DE, Dudman NP, Tyrrell PA. Homocystinuria due to cystathionine beta-synthase deficiency-the effects of betaine treatment in pyridoxine-responsive patients. Metabolism 1985;34:1115-21
34. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997;20:295-300
35. Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Parker PK. CMV beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001;12:563-73
36. Yap S, Boers GH, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER. Vascular outcome in patients with homocystinuria due to cystathionine -synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001;21:2080-5